Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]
Journal of Lipid Research, 2013 Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns +9 more
doaj
V280G Mutation, Potential Role in Imatinib Resistance: First Case Report
Clinical Medicine Insights: Oncology, 2017 Introduction: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction ...
Ana P Azevedo +5 more
doaj +1 more source
Bcr-abl-mediated Regulation of Sphingomyelin Synthase [PDF]
, 2012 SMS is an enzyme belonging to the sphingolipid metabolic pathway. Since the discovery and initial characterizations of sphingolipids (SLs) in 1884, extensive research has established that these molecules not only are structural components of eukaryotic ...
Burns, Tara Ann
core +1 more source
CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]
, 2008 The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi +55 more
core +3 more sources
DCAF16‐Based Covalent Molecular Glues for Targeted Protein Degradation of Histone Deacetylases
Archiv der Pharmazie, Volume 358, Issue 7, July 2025.Inspired by the recently identified vinylsulfonyl piperazine handle, which enables conjugation to protein of interest ligands for targeted protein degradation, a novel class of DCAF16‐based covalent molecular glues to degrade histone deacetylases (HDACs) was developed.
Tao Sun +6 more
wiley +1 more source
Case Reports in Hematology, 2018 We report the case of a 76-year-old man who was diagnosed as having chronic myeloid leukemia (CML) with p190 BCR-ABL while receiving treatment for symptomatic multiple myeloma (MM).
Kosuke Miki +11 more
doaj +1 more source
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. [PDF]
PLoS ONE, 2011 Amongst all leukemias, Bcr-Abl positive chronic myelogenous leukemia (CML) confers resistance to native drug due to multi drug resistance and also resistance to p53 and fas ligand pathways.
Abhalaxmi Singh +2 more
doaj +1 more source
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update [PDF]
, 2018 Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15–20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo-
Capitani, Silvano +6 more
core +1 more source
Cancer, Volume 131, Issue 13, 1 July 2025.Abstract Despite advances in acute myeloid leukemia (AML) treatment, significant unmet medical needs remain. Surrogate end points for overall survival can accelerate the approval of novel therapies. Measurable residual disease (MRD) is a promising surrogate end point candidate, providing a sensitive and quantitative assessment of disease burden ...
Michael Boyiadzis +20 more
wiley +1 more source
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]
, 2009 Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi +56 more
core +4 more sources